Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Capital Management Corp VA

Capital Management Corp VA trimmed its position in shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) by 11.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 290,350 shares of the biotechnology company’s stock after selling 38,270 shares during the period. Capital Management Corp VA owned approximately 1.99% of Anika Therapeutics worth $7,172,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in ANIK. Vanguard Group Inc. lifted its stake in shares of Anika Therapeutics by 1.3% in the first quarter. Vanguard Group Inc. now owns 773,702 shares of the biotechnology company’s stock worth $19,652,000 after acquiring an additional 9,657 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Anika Therapeutics by 6.9% during the 2nd quarter. Renaissance Technologies LLC now owns 598,229 shares of the biotechnology company’s stock valued at $15,153,000 after buying an additional 38,412 shares during the last quarter. Acadian Asset Management LLC grew its position in shares of Anika Therapeutics by 5.1% during the second quarter. Acadian Asset Management LLC now owns 442,944 shares of the biotechnology company’s stock worth $11,217,000 after buying an additional 21,517 shares in the last quarter. Meros Investment Management LP grew its position in shares of Anika Therapeutics by 25.0% during the second quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company’s stock worth $5,388,000 after buying an additional 42,587 shares in the last quarter. Finally, Stonepine Capital Management LLC increased its stake in shares of Anika Therapeutics by 171.4% in the second quarter. Stonepine Capital Management LLC now owns 165,397 shares of the biotechnology company’s stock worth $4,190,000 after buying an additional 104,448 shares during the last quarter. Hedge funds and other institutional investors own 91.53% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have weighed in on ANIK shares. StockNews.com lowered shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a report on Monday. Barrington Research decreased their price target on Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research note on Friday.

Anika Therapeutics Stock Up 3.3 %

Anika Therapeutics stock opened at $17.07 on Tuesday. Anika Therapeutics, Inc. has a 12 month low of $16.00 and a 12 month high of $29.11. The company has a fifty day moving average price of $24.45 and a two-hundred day moving average price of $25.58.

Anika Therapeutics (NASDAQ:ANIK) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share for the quarter, missing analysts’ consensus estimates of $0.23 by ($0.24). Anika Therapeutics had a negative net margin of 59.40% and a negative return on equity of 2.22%. The business had revenue of $41.92 million for the quarter, compared to the consensus estimate of $39.90 million. During the same period in the prior year, the company earned ($0.06) EPS. As a group, sell-side analysts expect that Anika Therapeutics, Inc. will post -0.1 EPS for the current year.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.